ARGX three-lens brief
Evidence-based stock research on ARGX. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Analyst mean target $1179.74 — 20% above current (23 analysts).
ARGX closed at $984.04 (-1.82%) as of 2026-09-11. Market cap: $61.56B. P/E (trailing) 38.2. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; analyst mean target $1179.74 — 20% above current (23 analysts).. Last quarter: Revenue $1.54B, net income $472.00M, free cash flow $761.77M.
Why three lenses on ARGX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ARGXacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ARGX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ARGX brief"></iframe>